AKR1C3 Inhibition: A Strategy to Reverse Osimertinib Resistance in Non-small Cell Lung Cancer
Abstract
Resistance to Osimertinib via the EGFR C797S mutation is a major challenge in the treatment of nonsmall cell lung cancer (NSCLC). Combining Osimertinib with SG-55, a novel selective AKR1C3 inhibitor, effectively reverses this resistance, restoring sensitivity in NSCLC cells with the C797S mutation. This highlights AKR1C3 inhibition in overcoming antitumor drug resistance for further preclinical investigation.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Pharmacogenetics and Drug Metabolism
Antibiotic Resistance in Bacteria
Publication details
- Journal / source
- Journal of Medicinal Chemistry
- Volume
- 69
- Issue
- 6
- Pages
- 6396–6398
- Publication date
- 13 March 2026
- Language
- EN